NYMOX PHARMACEUTICAL CORP (NYMX)
BSP733981026 - Common Stock
| MRQ (2023-3-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 351.00K | 1.40M | 830.00K | 3.61M | 5.24M | |||
| Receivables | 10.00K | 10.00K | 13.00K | 20.00K | 20.00K | |||
| Inventories | N/A | 0.00 | 34.00K | 30.00K | 20.00K | |||
| Other Current Assets | 100.00K | 44.00K | 160.00K | 230.00K | 50.00K | |||
| Total Current Assets | 461.00K | 1.46M | 1.04M | 3.89M | 5.33M | |||
| Non-Current Assets | ||||||||
| PPE Net | 114.00K | 168.00K | 406.00K | 450.00K | 160.00K | |||
| Other Non-Current Assets | N/A | N/A | N/A | N/A | 0.00 | |||
| Total Non-Current Assets | 114.00K | 168.00K | 406.00K | 450.00K | 160.00K | |||
| TOTAL ASSETS | 575.00K | 1.63M | 1.44M | 4.34M | 5.49M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 114.00K | 173.00K | 228.00K | 60.00K | 140.00K | |||
| Accrued Expenses | N/A | 237.00K | 285.00K | 320.00K | 270.00K | |||
| Accounts Payable | 2.26M | 1.70M | 1.27M | 1.40M | 1.63M | |||
| Other Current Liabilities | N/A | 0.00 | 0.00 | 50.00K | N/A | |||
| Total Current Liabilities | 2.37M | 2.11M | 1.79M | 1.83M | 2.04M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 163.00K | 370.00K | 0.00 | |||
| Other Non-Current Liabilities | N/A | N/A | N/A | N/A | N/A | |||
| Total Non-Current Liabilities | 0.00 | 0.00 | 163.00K | 370.00K | 0.00 | |||
| TOTAL LIABILITIES | 2.37M | 2.11M | 1.95M | 2.20M | 2.04M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -200.53M | -199.14M | -192.56M | -180.03M | -168.29M | |||
| Additional Paid In Capital | 27.05M | 26.98M | 27.58M | 31.04M | 35.77M | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 171.67M | 171.67M | 165.06M | 151.72M | 136.55M | |||
| Other Shareholders' Equity | 0.00 | 0.00 | -589.00K | -590.00K | -590.00K | |||
| Shares Outstanding | 90.52M | 90.52M | 85.55M | 77.96M | 71.22M | |||
| Tangible Book Value per Share | -0.02 | -0.01 | -0.01 | 0.03 | 0.05 | |||
| Total Shareholders' Equity | -1.80M | -482.00K | -506.00K | 2.15M | 3.45M | |||
| TOTAL LIABILITIES AND EQUITY | 575.00K | 1.63M | 1.44M | 4.34M | 5.49M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | -0.32 | 0.17 | N/A | |||
| Current Ratio | 0.19 | 0.69 | 0.58 | 2.13 | 2.61 | |||
| Return On Assets (ROA) | -500.35% | -404.68% | -868.81% | -270.51% | -239.71% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | -546.05% | -381.45% | |||
All data in USD